HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

Authors

Institutions

Publication Details

Journal
Turkish Journal of Clinics and Laboratory
Published
2025-06-30
DOI
https://doi.org/10.18663/tjcl.1639022
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Merve Keskinkılıç, İbrahim Vedat Bayoğlu, Hacer Demir, Naziyet Köse Baytemür et al.
1 citations
Turkish Journal of Clinics and Laboratory
Advanced Breast Cancer Therapies
1.52
article

HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Merve Keskinkılıç, İbrahim Vedat Bayoğlu, Hacer Demir, Naziyet Köse Baytemür, Semra Paydaş, Hakan Yücel, Burçin Çakan Demirel, Cihan Erol, Eda Eylemer Mocan, Seda Kahraman, Arzu Yaren, Gül Başaran, Aydın Dincer, Burak Bi̇lgi̇n, Kerem Okutur, Nurhan Önal Kalkan, Ömer Acar, Özgecan Dülgar, Özge Gümüşay, Atike Pınar Erdoğan, İlhan Hacıbekiroğlu, Ali İnal, Orhan Önder Eren, Murat Keser, Erdem Çubukçu, Yusuf Karakaş, Adnan Aydıner, Burcu Gülbağcı, Teoman Şakalar, Mehmet Alı Nahıt Şendur, Musa Barış Aykan, Yakup İriağaç, Mutlu Hızal, Nail Paksoy, Mustafa Seyyar, Özlem Doğan, Umut Demırcı, Erkan Kayıkçıoğlu, Nazım Serdar Turhal, Bülent Çetin, Ertuğrul Bayram, Berna Bozkurt Duman, Veli Sunar, Melike Özçelik, Fatih Selçukbırıcık, Esra Aydın, Mutlu Doğan, Muhammed Muhiddin Er, Başak Oyan Uluç, Devrim Çabuk, Deniz Işık, Muhammed Bülent Akıncı, Serkan Menekşe, Engin Kut, Gülhan Özkanlı, Elif Şahin, Alper Yaşar, Sena Ece Davarcı, Funda Yılmaz, Özlem Özdemir, Deniz Can Güven, Sibel Oyucu Orhan, Nilgün Yıldırım, Olçun Ümit Ünal, Müge Karaoğlanoğlu
article en
1 citations

Abstract

Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

Turkish Journal of Clinics and LaboratoryVol. 16(2)
Sakarya University (TR), Çanakkale Onsekiz Mart Üniversitesi (TR), Van Yüzüncü Yıl Üniversitesi (TR), Tekirdağ Namık Kemal University (TR), Bursa Uludağ Üni̇versi̇tesi̇ (TR), Izmir University (TR), Anadolu University (TR), Koç University (TR), Selçuk University (TR), Fırat University (TR), Ankara University (TR), Recep Tayyip Erdoğan University (TR), Manisa Celal Bayar University (TR), Bilkent University (TR), Dokuz Eylül University (TR), State Hospital (GB), Acıbadem University (TR), Memorial Ankara Hospital (TR), Necmettin Erbakan University (TR), Nara City Hospital (JP), Suleyman Demirel University (KZ), City Hospital (GB), Sağlık Bilimleri Üniversitesi (TR), Universidad CES (CO), Ankara Yıldırım Beyazıt University (TR), Acıbadem Adana Hospital (TR), Afyonkarahisar Sağlık Bilimleri Üniversitesi, University of Health Sciences (SO), Ankara Bilkent City Hospital (TR), Pamukkale University (TR), Istanbul Arel University (TR), Mersin Üniversitesi (TR), Kocaeli Üniversitesi (TR), Cukurova University (TR), Gaziantep University (TR), Ordu University (TR), Hacettepe University (TR), Istanbul University (TR), Marmara University (TR), University of Health Sciences Antigua (AG)
Openalex Percentile: Top 17%
Advanced Breast Cancer Therapies
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.